Contrast agent developer Palatin Technologies has concluded an offering that raised approximately $22.7 million from sale of common stock and warrants to primarily institutional investors.
The proceeds will be used to continue development of the firm's PT-142 therapeutic candidate for treatment of male and female sexual dysfunction, its LeuTech monocolonal antibody for imaging and diagnosing infections, as well as for drug discovery efforts, and general corporate purposes, according to the Cranbury, NJ-based firm.
By AuntMinnie.com staff writers
January 30, 2004
Related Reading
Palatin raises $19 million, April 1, 2003
Palatin fattens coffers for research, November 20, 2002
Palatin’s revenues down, losses up in fiscal 2002, October 1, 2002
Palatin adds to war chest, August 2, 2002
Palatin, Mallinckrodt restructure deal, May 15, 2002
Copyright © 2004 AuntMinnie.com
